| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
90,630,000 |
| Market
Cap: |
15.17(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$129.52 - $242.06 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 664 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BeiGene is a commercial-stage biotechnology company focused on developing and commercializing molecularly-targeted and immuno-oncology cancer therapeutics. Co.'s clinical-stage drug candidates include: Zanubrutinib, which is a small molecule inhibitor of Bruton's tyrosine kinase for the treatment of mantle cell lymphoma in adult patients; Tislelizumab, which is a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1; Pamiparib (BGB-290), which is for the treatment of various solid tumors; and Lifirafenib, which is an investigational small molecule inhibitor with RAF monomer and dimer inhibition activities.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
100,397 |
100,397 |
5,364,251 |
5,588,274 |
| Total Sell Value |
$15,909,372 |
$15,909,372 |
$1,039,781,980 |
$1,085,894,829 |
| Total People Sold |
2 |
2 |
8 |
9 |
| Total Sell Transactions |
6 |
6 |
20 |
54 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wang Xiaodong |
Chair, Scientific Advisory Brd |
– • – |
2019-07-01 |
4 |
AS |
$126.13 |
$612,937 |
D/D |
(4,847) |
0 |
|
- |
|
| Huang Jane |
CMO, Hematology |
• – – |
2019-06-27 |
4 |
AS |
$124.50 |
$53,542 |
D/D |
(430) |
0 |
|
- |
|
| Liang Howard |
CFO & Chief Strategy Officer |
• – – |
2019-06-27 |
4 |
S |
$9.47 |
$55,653 |
D/D |
(5,876) |
122,317 |
|
- |
|
| Yi Qingqing |
Director |
– • – |
2019-06-17 |
4 |
D |
$0.00 |
$0 |
D/D |
(9,282) |
0 |
|
- |
|
| Baker Julian |
Director |
– • • |
2019-06-06 |
4 |
A |
$0.00 |
$0 |
D/D |
86,218 |
43,109 |
|
- |
|
| Baker Julian |
Director |
– • • |
2019-06-06 |
4 |
D |
$0.00 |
$0 |
I/I |
(582,200) |
18,591 |
|
- |
|
| Baker Julian |
Director |
– • • |
2019-06-06 |
4 |
A |
$0.00 |
$0 |
D/D |
27,032 |
20,618 |
|
- |
|
| Baker Julian |
Director |
– • • |
2019-06-06 |
4 |
D |
$0.00 |
$0 |
I/I |
(182,539) |
1,028,034 |
|
- |
|
| Liang Howard |
CFO & Chief Strategy Officer |
• – – |
2019-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
75,855 |
128,193 |
|
- |
|
| Huang Jane |
CMO, Hematology |
• – – |
2019-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
62,842 |
334,463 |
|
- |
|
| Wu Xiaobin |
President & GM China |
• – – |
2019-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
433,472 |
1,505,956 |
|
- |
|
| Huang Jane |
CMO, Hematology |
• – – |
2019-05-21 |
4 |
AS |
$130.06 |
$286,132 |
D/D |
(2,200) |
0 |
|
- |
|
| Huang Jane |
CMO, Hematology |
• – – |
2019-05-21 |
4 |
OE |
$45.31 |
$99,682 |
D/D |
2,200 |
2,200 |
|
- |
|
| Liang Howard |
CFO & Chief Strategy Officer |
• – – |
2019-05-21 |
4 |
AS |
$130.21 |
$3,020,860 |
D/D |
(23,200) |
0 |
|
- |
|
| Liang Howard |
CFO & Chief Strategy Officer |
• – – |
2019-05-21 |
4 |
OE |
$6.50 |
$150,800 |
D/D |
23,200 |
23,200 |
|
- |
|
| Huang Jane |
CMO, Hematology |
• – – |
2019-05-20 |
4 |
AS |
$130.12 |
$39,036 |
D/D |
(300) |
0 |
|
- |
|
| Huang Jane |
CMO, Hematology |
• – – |
2019-05-20 |
4 |
OE |
$45.31 |
$13,593 |
D/D |
300 |
300 |
|
- |
|
| Liang Howard |
CFO & Chief Strategy Officer |
• – – |
2019-05-06 |
4 |
AS |
$130.01 |
$234,014 |
D/D |
(1,800) |
0 |
|
- |
|
| Liang Howard |
CFO & Chief Strategy Officer |
• – – |
2019-05-06 |
4 |
OE |
$6.50 |
$11,700 |
D/D |
1,800 |
1,800 |
|
- |
|
| Wu Xiaobin |
President & GM China |
• – – |
2019-05-01 |
4 |
S |
$124.47 |
$741,546 |
D/D |
(5,955) |
17,365 |
|
- |
|
| Oyler John |
Chief Executive Officer |
• • – |
2019-05-01 |
4 |
AS |
$124.79 |
$353,505 |
D/D |
(2,824) |
0 |
|
- |
|
| Huang Jane |
CMO, Hematology |
• – – |
2019-04-08 |
4 |
AS |
$140.49 |
$2,017,315 |
D/D |
(14,130) |
0 |
|
- |
|
| Huang Jane |
CMO, Hematology |
• – – |
2019-04-08 |
4 |
OE |
$29.49 |
$416,694 |
D/D |
14,130 |
14,130 |
|
- |
|
| Glazer Donald W. |
Director |
– • – |
2019-03-14 |
4 |
S |
$136.10 |
$2,037,825 |
D/D |
(14,973) |
0 |
|
- |
|
| Wang Xiaodong |
Director |
– • – |
2019-03-13 |
4 |
GD |
$0.00 |
$0 |
D/D |
20,969 |
7,674,639 |
|
- |
|
527 Records found
|
|
Page 15 of 22 |
|
|
6.93 (3.98%) 
